Table 2

Regulatory letters by releasing division/office, 1997–2011
Administration Clinton 2nd administration Bush administrations Obama administration All
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Total
Prescription Drug Promotion 140 162 108 79 69 27 25 23 29 22 20 21 43 52 30 850
Office of Scientific Investigations 2 4 8 5 11 2 2 3 6 9 10 16 20 15 18 131
Compliance 1 1 2 12 19 10 2 1 40 17 105
Manufacturing and Product Quality 14 7 5 11 6 1 1 3 2 3 4 8 16 17 98
Security, Integrity and Recalls 7 8 1 1 4 1 20 3 6 6 2 59
Compliance Risk Management and Surveillance 1 1
Drugs and Labeling Compliance 1 1
Prescription Drug Compliance 1 1
Manufacturing and Product Quality/Division of Compliance Risk Management and Surveillance 1 1
Unapproved Drugs and Labeling Compliance 1 1
District Offices 94 116 96 98 108 81 58 71 60 81 29 85 60 89 93 1,219
Total 258 299 219 195 196 123 105 108 102 117 83 129 177 195 161 2,467

Note: 1 letter released in 1998 by the OMPQ was coauthored by the Division of Prescription Drug Compliance and Surveillance. The names of the Divisions and Offices changed over time. The most current names are included in the table.

Nguyen et al.

Nguyen et al. BMC Health Services Research 2013 13:27   doi:10.1186/1472-6963-13-27

Open Data